TG Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +66.6% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 18.8% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 94.5x | Better than 4% |
| Forward P/E | 24.2x | Better than 27% |
| Price / Sales | 10.9x | Better than 10% |
| P/E vs own 5-yr range | 88th pctl | Better than 18% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability A+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 83.7% | Better than 93% |
| Operating margin | 20.0% | Better than 76% |
| Net margin | 72.6% | Better than 99% |
| Return on equity | 102.8% | Better than 98% |
| Return on invested capital | 67.8% | Better than 99% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 16.7% | Better than 95% |
| 6-month return | 63.0% | Better than 97% |
| 12-month return (ex latest month) | 69.5% | Better than 90% |
| Distance below 52-week high | 6.9% | Better than 91% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.1x | Better than 82% |
| Debt to assets | 23.9% | Better than 50% |
| Interest coverage | 5.0x | Better than 56% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 20.6% | Better than 34% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 64.88
- Open
- 64.10
- Day range
- 63.12 - 65.64
- Avg price
- 64.03
- Volume
- 2.09M
- Turnover
- 133.78M
- Turnover ratei
- 1.45%
- Volume ratioi
- 1.29
- Amplitudei
- 3.89%
- 52-week rangei
- 26.76 - 68.03
Valuation
- P/Ei
- 22.87
- P/E (TTM)i
- 94.54
- P/Bi
- 16.73
- EPSi
- 2.77
- Book value / shi
- 3.79
- Net profit
- 418.68M
- Net assets
- 572.09M
Share structure
- Market cap
- 9.57B
- Float capi
- 9.16B
- Shares out
- 151.15M
- Float sharesi
- 144.54M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
6.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-2.40M net over the window
Short interest
- Shares short
- 28.77M
- % of floati
- 18.79%
- Days to coveri
- 18.89
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of TG Therapeutics (TGTX)?
TG Therapeutics last traded at 63.34. This page shows a periodic quote snapshot. Check the displayed quote time.
What is TG Therapeutics's market cap?
About 9.57B.
What is the P/E ratio of TG Therapeutics?
The trailing twelve-month P/E is 94.54, above its own 5-year average of 7.41 — toward the top of its historical range (87.56% percentile). See the Valuation tab for the full history.
Does TG Therapeutics pay a dividend?
TG Therapeutics does not currently pay a regular dividend.
Is TG Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 76.40, which implies 20.6% upside from the current price. This is not investment advice.
What is TG Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates TG Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:20 · For reference only, not investment advice and not tailored to your situation.
TG Therapeutics discussion 0 comments